Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting

MT Newswires Live01-27 10:38

Mesoblast (ASX:MSB) said 21 of the first 25, or 84%, patients treated with its Ryoncil product in a "real-world" clinical setting post-launch were alive and completed the initial 28-day treatment regimen as per the US Food and Drug Administration (FDA) approval label, according to a Tuesday Australian bourse filing.

The four remaining patients had been offered and failed other therapies before the use of Ryoncil and died of severe steroid-refractory acute graft-versus-host disease within 28 days, per the filing.

The firm established a patient access hub termed MyMesoblast to allow patients to order Ryoncil. It has onboarded 45 transplant centers, and it is targeting the onboarding of 64 centers.

Its shares fell nearly 1% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment